A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 338
- Registration Number
- NCT03852251
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 94
- Registration Number
- NCT03722147
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beiing, China
© Copyright 2024. All Rights Reserved by MedPath